Literature DB >> 9741458

Comparative histopathology of hepatic allografts and xenografts in the nonhuman primate.

Y Luo1, S Kosanke, L Mieles, T Kobayashi, S F Li, M Niekrasz, A Shimizu, Y Ye, R B Colvin, D K Cooper.   

Abstract

Liver transplantation was performed in the following groups: Group 1, baboon-to-baboon allografting (n=8) (control group); Group 2, ABO-compatible vervet monkey-to-baboon xenografting (n=8); Group 3, ABO-incompatible vervet monkey-to-baboon xenografting (n=6); Group 4, pig-to-baboon xenografting (n=2); and Group 5, pig-to-rhesus monkey xenografting (n=6). Immunosuppressive therapy (cyclosporine, cyclophosphamide, and methylprednisolone) was begun 2-7 days before liver transplantation (LTx) and continued indefinitely after LTx. The liver grafts were biopsied pre-LTx and subsequently post-LTx at approximately 1 hr, 2-3 hr, 7-10 days, 20-30 days, 60 days, 120 days, and at euthanasia or spontaneous death. There were 19 successful LTxs with grafts functioning from one hour to 123 days. No pig liver (Groups 4 and 5) survived more than 5.5 hr, as there was an immediate severe vascular response after reperfusion, typical of hyperacute rejection (congestion and hemorrhage). Vascular rejection was not seen in allografts (Group 1), but early mild-to-moderate congestion and neutrophil infiltration were present in concordant xenografts (Groups 2 and 3), which were associated with moderate deposition of immunoglobulin, C3, and fibrinogen. Lymphoid cell infiltration, bile duct damage, and portal vein endothelialitis in the portal zones occurred later in both allografts (Group 1) and concordant xenografts (Groups 2 and 3), developing earlier in the presence of ABO-incompatibility (Group 3). In concordant xenografts it was usually followed by fibrosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9741458     DOI: 10.1111/j.1399-3089.1998.tb00028.x

Source DB:  PubMed          Journal:  Xenotransplantation        ISSN: 0908-665X            Impact factor:   3.907


  7 in total

Review 1.  A review of pig liver xenotransplantation: Current problems and recent progress.

Authors:  Xuan Zhang; Xiao Li; Zhaoxu Yang; Kaishan Tao; Quancheng Wang; Bin Dai; Shibin Qu; Wei Peng; Hong Zhang; David K C Cooper; Kefeng Dou
Journal:  Xenotransplantation       Date:  2019-02-15       Impact factor: 3.907

Review 2.  Liver xenotransplantation.

Authors:  Madhukar S Patel; Nathan Louras; Parsia A Vagefi
Journal:  Curr Opin Organ Transplant       Date:  2017-12       Impact factor: 2.640

Review 3.  Use and Importance of Nonhuman Primates in Metabolic Disease Research: Current State of the Field.

Authors:  Peter J Havel; Paul Kievit; Anthony G Comuzzie; Andrew A Bremer
Journal:  ILAR J       Date:  2017-12-01

Review 4.  Immunobiology of liver xenotransplantation.

Authors:  Burcin Ekser; Christopher Burlak; Joshua P Waldman; Andrew J Lutz; Leela L Paris; Massimiliano Veroux; Simon C Robson; Michael A Rees; David Ayares; Bruno Gridelli; A Joseph Tector; David Kc Cooper
Journal:  Expert Rev Clin Immunol       Date:  2012-09       Impact factor: 4.473

Review 5.  Pig liver xenotransplantation as a bridge to allotransplantation: which patients might benefit?

Authors:  Burcin Ekser; Bruno Gridelli; A Joseph Tector; David K C Cooper
Journal:  Transplantation       Date:  2009-11-15       Impact factor: 4.939

Review 6.  Pig Liver Xenotransplantation: A Review of Progress Toward the Clinic.

Authors:  David K C Cooper; Ke-Feng Dou; Kai-Shan Tao; Zhao-Xu Yang; A Joseph Tector; Burcin Ekser
Journal:  Transplantation       Date:  2016-10       Impact factor: 4.939

7.  Genetically-engineered pig-to-baboon liver xenotransplantation: histopathology of xenografts and native organs.

Authors:  Burcin Ekser; Edwin Klein; Jing He; Donna B Stolz; Gabriel J Echeverri; Cassandra Long; Chih Che Lin; Mohamed Ezzelarab; Hidetaka Hara; Massimiliano Veroux; David Ayares; David K C Cooper; Bruno Gridelli
Journal:  PLoS One       Date:  2012-01-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.